Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET C634W |
| Therapy | Pralsetinib |
| Indication/Tumor Type | medullary thyroid carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET C634W | medullary thyroid carcinoma | sensitive | Pralsetinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Gavreto (pralsetinib) inhibited Ret signaling and proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture, and inhibited tumor growth in xenograft models (PMID: 29657135). | detail... 29657135 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers | Full reference... | |
| (29657135) | Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. | Full reference... |